Breast Cancer and Menopause. About 95% of women diagnosed with breast cancer each year are over age 40, Hormone replacement therapy may be given to postmenopausal women . The goal of endocrine therapy is to prevent breast cancer cells from being stimulated by estrogen. In postmenopausal women with early hormone-responsive breast cancer, the two endocrine treatments most often used are the class of drugs called selective estrogen receptor modulators (SERMs) or another class called aromatase inhibitors (AIs).
Objective: Breast cancer is the most common female cancer worldwide and is the second most commonly diagnosed cancer in Indian women. This study evaluates the differences between pre- and post-menopausal breast cancer women regarding risk factors, nature of disease presentation, tumor characteristics, and management. Have a history of breast cancer. Have a higher risk of breast cancer. Sometimes, women receive HRT at a low dose. This is done for a short time for severe menopausal symptoms. Other times, doctors consider HRT with estrogen alone. This option is only for women who have had a hysterectomy. A hysterectomy is the surgical removal of the uterus.
Aug 21, 2017 · Many women have menopause symptoms such as hot flashes after treatment for breast cancer. This can happen naturally as women get older, but it can also be caused by breast cancer treatment. Some pre-menopausal women have menopause symptoms as a Last Revised: August 21, 2017. Oct 03, 2018 · Which means that weight gain, in particular, is a risk factor for postmenopausal breast cancer, since more fat cells mean more estrogen. Studies show that women who are overweight or obese after menopause have a 20 to 60 percent higher breast cancer risk than those who are lean.Author: Barbara Stepko.
Aromatase inhibitors stop the production of estrogen in postmenopausal women. Aromatase inhibitors work by blocking the enzyme aromatase, which turns the hormone androgen into small amounts of estrogen in the body. This means that less estrogen is available to stimulate the growth of hormone-receptor-positive breast cancer cells. A third aromatase inhibitor, exemestane, is approved for adjuvant treatment of early-stage breast cancer in postmenopausal women who have received tamoxifen previously. Until recently, most women who received adjuvant hormone therapy to reduce the chance of a breast cancer recurrence took tamoxifen every day for 5 years.
Clinical trial results presented at the 2011 ASCO annual meeting showed that the aromatase inhibitor exemestane—used to treat early and advanced breast cancer—substantially reduced the risk of invasive breast cancer in high-risk postmenopausal women. Feb 05, 2009 · Following the release of the 2002 report of the Women’s Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy in the United States decreased substantially. Subsequently, the incidence of breast cancer also dropped, suggesting a Cited by: 537.